Abstract | OBJECTIVE: DATA SOURCE: Published research and review articles (PubMed, from 1985 to 2003) relating to clinical trials of compounds involving the protein C pathway. DATA EXTRACTION AND SYNTHESIS: CONCLUSIONS: Treatment with protein C concentrate is followed by an improvement of the coagulopathy and is safe in children with purpura fulminans; however, a large trial involving a high dose is required to determine its effect on mortality and morbidity. Treatment with drotrecogin alfa (activated) leads to substantial reduction in mortality and has an acceptable risk/benefit ratio in septic patients at high risk of death.
|
Authors | Jean-François Dhainaut, S Betty Yan, Yann-Erick Claessens |
Journal | Critical care medicine
(Crit Care Med)
Vol. 32
Issue 5 Suppl
Pg. S194-201
(May 2004)
ISSN: 0090-3493 [Print] United States |
PMID | 15118517
(Publication Type: Journal Article, Review)
|
Chemical References |
- Protein C
- Recombinant Proteins
|
Topics |
- Clinical Trials as Topic
- Humans
- Protein C
(physiology, therapeutic use)
- Recombinant Proteins
(therapeutic use)
- Sepsis
(drug therapy, immunology)
- Severity of Illness Index
|